Abstract: Amorphous rifaximin, methods of making it, and pharmaceutical compositions containing it. Also described are methods of converting amorphous rifaximin to crystalline rifaximin and vice versa.

Abstract: A pulsed UV disinfection system includes a xenon UV lamp mounted in an articulated head assembly and a chassis housing a high voltage power supply for driving the lamp and a pulse configuration control unit for configuring the output of the power supply. The head assembly and the chassis are positioned on a mobile carriage. The pulse configuration control unit is programmed for driving the UV lamp at a rate of between 20 and 50 pulses per second, with each pulse emitting between 30 and 150 joules of UV radiant energy. The system also features remote video imaging of a target area, remote control of the carriage and head assembly as well as a remote emergency shutdown.

Abstract: A method, system and computer program product for estimating report generation time are disclosed. The method includes receiving an indication that a user is requesting a report from a database application. An estimated amount of time for the database application to generate the report is calculated, and the estimated amount of time is displayed to the user.

Abstract: Amorphous rifaximin, methods of making it, and pharmaceutical compositions containing it. Also described are methods of converting amorphous rifaximin to crystalline rifaximin and vice versa.

Abstract: A method, an apparatus, and a computer-readable medium for wireless communication are provided. The apparatus may include memory and at least one processor, coupled to the memory, configured to determine a power parameter associated with communication using a first radio access technology (RAT). The at least one processor may be further configured to determine a quality parameter associated with the communication using the first RAT. The at least one processor may be further configured to apply, based on the quality parameter, an offset to the power parameter to form a modified power parameter. The at least one processor may be further configured to transmit a measurement report including the modified power parameter. The apparatus may be a wireless device, such as a user equipment (UE) and, more specifically, a high gain UE.

Abstract: The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, thereof, wherein: G is a group of formula (II): and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates, thereof, wherein A, B, L1-L4, A, B, R1-R4, and m are as defined herein. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and their use in treating a bacterial infection.

Abstract: Certain aspects of the claimed invention generally relate to a network dynamically configuring one or more cells based on signal quality measurements received from all antennas of a receiver-limited UE. The receiver-limited UE may have a number of receivers that is less than or equal to a number of antennas of the UE. Further, the UE may be capable of operating in a CA mode. Dynamically configuring the one or more cells based, at least in part, on the received signal quality measurements may allow the UE to operate on M×N MIMO on the Pcell or Scell.

Abstract: The present invention provides a compound of the Formula (I) wherein R is 9-isopropyl-9H-purin-6-amine; 2-amino-9-isopropyl-1H-purin-6(9H)-one; 4-amino-1-isopropyl pyrimidin-2(1H)-one; or 1-isopropyl-5-methylpyrimidine-2,4(1H,3H)-dione, R? is —CH2OC(O)R?, and R? is —C(CH3)3 or —CH(CH3)2 including pharmaceutically acceptable salts thereof. The present invention also provides a process for preparing a compound of formula (Ia) and a compound of formula (I) for use in treating a viral infection.

Abstract: The present invention provides a compound of the Formula (I) wherein R is 9-isopropyl-9H-purin-6-amine; 2-amino-9-isopropyl-1H-purin-6(9H)-one; 4-amino-1-isopropyl pyrimidin-2(1H)-one; or 1-isopropyl-5-methylpyrimidine-2,4(1H,3H)-dione, R? is —CH2OC(O)R?, and R? is —C(CH3)3 or —CH(CH3)2 including pharmaceutically acceptable salts thereof. The present invention also provides a process for preparing a compound of formula (Ia) and a compound of formula (I) for use in treating a viral infection.

Abstract: Amorphous rifaximin, methods of making it, and pharmaceutical compositions containing it. Also described are methods of converting amorphous rifaximin to crystalline rifaximin and vice versa.

Abstract: A system and method for wireless communication reduces the number of number of preambles transmitted in a random access channel (RACH) process. The RACH preamble is transmitted at a maximum transmit power. When a RACH response has not been received, the maximum transmit power is adjusted.

Abstract: A method and apparatus for protecting sensitive information from disclosure through virtual machine files is disclosed. In one embodiment, the method includes processing virtual machine files using at least one processor to access data objects in memory that are associated with at least one virtual machine, examining the data objects using the at least one processor in accordance with a data loss prevention policy in the memory to identify, using the at least one processor, sensitive information within at least one data object of the data objects and securing, using the at least one processor, the sensitive information within the virtual machine files in the memory.

Abstract: There is disclosed crystalline darunavir hydrate substantially free of any non-aqueous solvent.

Abstract: In an embodiment, the present invention provides a process for preparing (?)-6-(4-aminophenyl)-5-methylpyridazin-3-(2H)-one, which process comprises: a) reacting racemic 6-(4-aminophenyl)-4,5-dihydro-5-methyl-3-(2H)-pyridazinone of formula II with a chiral tartaric acid derivative to obtain a diastereomeric salt of (?)-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3-(2H)-pyridazinone and the chiral tartaric acid derivative; and b) reacting the diastereomeric salt with a base to obtain (?)-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3-(2H)-pyridazinone. The (?)-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3-(2H)-pyridazinone may be used to prepare levosimendan.

Abstract: The present invention provides a process for preparing methyl 5-acetamido-4-amino-6-(1,2,3-triacetoxypropyl)-5,6-dihydro-4H-pyran-2-carboxylate (V), which process comprises reducing methyl 5-acetamido-4-azido-6-(1,2,3-triacetoxypropyl)-5,6-dihydro-4H-pyran-2-carboxylate (IV) in the presence of a reducing agent selected from the group consisting of lithium aluminum hydride, sodium borohydride, zinc/ammonium chloride, zinc-ferric chloride and ferric chloride/sodium iodide. The present invention also provides compounds of formula (VIII) and (IX) which may be used in the synthesis of zanamivir. The present invention also provides processes for preparing compounds (VIII) and (IX) and processes involving their use, including in the synthesis of zanamivir.

Abstract: A method, an apparatus, and a computer program product for wireless communication are provided. The apparatus may include at least one processor configured to initiate a voice call using a first network, determine that a condition exists, and switch the voice call from the first network to a second network after the determination that the condition exists. The first network may be a packet-switched network, the second network may a circuit-switched network, and the condition may be that the packet-switched network has poor coverage quality. Alternatively, the first network may be a circuit-switched network, the second network may a packet-switched network, and the condition may be that the packet-switched network has improved coverage quality. Optionally, a user may be prompted to perform the switch and the user may provide an input to perform the switch. The switch may performed using SRVCC or RRC signaling.

Abstract: Valve members include a metal he body having a head. with a circular-shaped side section extending axially therefrom. A composite seal is adjacent the side section, and extends circumferentially therearound. The composite seal has an elastomeric body with an inner diameter in contact with the side section, and an outside surface extending away from the side section. A non-elastomeric material is attached to the elastomeric body.

Abstract: Methods, systems, and devices are described for triggering an antenna switch. A settling time may be identified, and the antenna switch may be delayed based at least in part on the identified settling time. The settling time may include an estimated delay in reception attributable to settling following the antenna switch.

Abstract: The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, thereof, wherein: G is a group of formula (II): and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates, thereof, wherein A, B, L1-L4, A, B, R1-R4, and m are as defined herein. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and their use in treating a bacterial infection.

Abstract: Methods, systems, and devices are described for thermal management of a wireless communication device. The described techniques may be used, for example, to monitor an operating temperature of the device to determine if the operating temperature has exceeded a threshold value. Other aspects may provide for monitoring of a PA temperature, a transmission power level, and/or input from one or more additional sensors associated with the wireless communication device. Based on any of the above inputs, alone or in combination, an operating temperature of the wireless communication device may be determined When the temperature exceeds the threshold value, a transmission antenna can be switched from a first antenna to a second antenna. Additional aspects may provide for reduction of the transmission power level in response to the operating temperature exceeding the predetermined threshold value.